Walden Group Healthcare M&A Blog

  • Exact Sciences to buy Genomic Health for $2.8b

    Exact Sciences Corp, a $454m molecular diagnostics company is acquiring Genomic Health Inc, a $394m cancer detection company for $2.8b. The deal joins two of the strong brands in molecular and cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth; and forms a first class commercial, research,...
    Read More
  • Cantel Medical to Acquire Hu-Friedy for $725m

    Cantel Medical Corp., a $880m manufacturer of medical equipment announced plans to buy Hu-Friedy Mfg. Co., a maker of dental instruments and reprocessing equipment for $725m. The deal helps build out a portfolio of infection prevention solutions including consumables, instrumentation and workflow management programs for dental practitioners while...
    Read More
  • AbbVie to Buy Allergan for $63b

    AbbVie Inc., a $32.75b pharmaceutical company agreed to buy Allergan plc, an Ireland-based $15.79b pharmaceutical company for $63b. The latest merger in an industry where huge premiums are being paid to incease growth prospects. The deal gives AbbVie Botox, but doesn’t involve a huge pipeline of blockbuster drugs. Allergan does diversify AbbVie...
    Read More
  • The Walden Group advises Riverpoint Medical, LLC in its Partnership with Arlington Capital Partners and Helps Guide the Transaction to a Successful Closing

    The Walden Group, Inc. is pleased to announce that Arlington Capital Partners has acquired a majority interest in its client, Riverpoint Medical, LLC. Riverpoint is a major developer and manufacturer of advanced bioabsorbable and non-absorbable sutures; high-strength fiber implantables for sports medicine surgery; patented cordless surgeon...
    Read More
  • FDA Bans Sales of Transvaginal Mesh

    The FDA has ordered the two remaining medical device companies, Boston Scientific and Coloplast, selling surgical mesh for the repair of pelvic organ prolapse to stop all sales and distribution in the US. The FDA said the two companies did not demonstrate a reasonable assurance of safety and effectiveness of these devices in their premarket...
    Read More